Study to Assess if Internet-Based Tailored Advice Could Modify Behaviour to Improve Health

This study has been completed.
Sponsor:
Collaborators:
Lipid and Cardiovascular Risk Assessment Service, ICPMR, Westmead Hospital
Royal Prince Alfred Hospital, Sydney, Australia
Pfizer
Medical benefit Fund (MBF)
Information provided by:
The George Institute
ClinicalTrials.gov Identifier:
NCT00220974
First received: September 13, 2005
Last updated: February 11, 2009
Last verified: February 2009
  Purpose

The purpose of this trial is to find out if a special website might help people discover if they have high cholesterol and then enable them to manage their cholesterol more appropriately. The primary aim of this trial is to determine the effects on consumers' use of cholesterol lowering therapy of an online service that provides automated, individually tailored, advice about eligibility for cholesterol lowering treatment. The primary null hypothesis being tested is that the service will result in no change in the use of cholesterol lowering treatments by consumers that use the service.

The secondary aim of the trial is to see if it is possible to improve the cholesterol management of the friends or relatives of consumers that use the I-CAT service. The corresponding secondary null hypothesis being tested is that the I-CAT service will result in no change in the use of cholesterol lowering treatments by the friends or relatives of the consumers that use the service.


Condition Intervention
Hypercholesterolemia
Behavioral: Internet-based tailored advice on cardiovascular risk

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Official Title: Internet-Based Cholesterol Assessment Trial

Resource links provided by NLM:


Further study details as provided by The George Institute:

Primary Outcome Measures:
  • To determine the effectiveness of a consumer-mediated, Internet-based strategy for identification and intervention in hypercholesterolemia.

Secondary Outcome Measures:
  • To determine the effectiveness of a consumer-mediated, Internet-based strategy in the adoption of healhier behaviour and lifestyle

Estimated Enrollment: 3708
Study Start Date: October 2004
Study Completion Date: December 2006
Primary Completion Date: December 2006 (Final data collection date for primary outcome measure)
Detailed Description:

The Internet-based Cholesterol Assessment Trial (I-CAT) is a masked, randomised, controlled trial that will include at least 3,700 consumers followed for between 8 and 16 weeks. All consumers that participate in the study will ultimately be offered the I-CAT service, which provides individually tailored information about the management of cholesterol-related risk via an interactive website. However, by offering the service immediately to one group (intervention) and delaying it by 8 weeks in the other group (control) it will be possible to precisely and reliably determine the effects of the I-CAT service on consumers and their use of cholesterol lowering interventions.

There will be two types of individuals involved in the study: 'index cases' and 'friends or relatives' of the index cases. The index cases will be randomised to intervention or control and will comprise the study participants on which the main outcome analyses will be based. Friends and relatives of the index case will only be involved insomuch as they will be asked to visit the site by the index case as part of the evaluation of the effectiveness of the intervention.

Index cases will comprise mainly individuals already known to be at high risk of a cholesterol-related disease event - for example individuals with established vascular disease, individuals with multiple risk factors and individuals already using cholesterol-lowering therapy. Index cases will be recruited using advertising materials placed at a range of sites including hospital in patient services, hospital out patient services, general practices, pharmacies, pathology services and the Internet.

All individuals that provide informed consent (index cases and friends or relatives) will be asked to answer as many questions as possible from the XX questions in the baseline questionnaire. The questionnaire will seek information about the individual's cardiovascular disease history, their risk factors, their cholesterol levels, their use of any medications or other strategies to reduce their cholesterol-related cardiovascular risk and any family history of cardiovascular disease or high cholesterol levels.

Once baseline data collection is complete index cases will be randomised to either intervention or control. Randomisation will be done automatically in real time by a central computerised service. The intervention group will receive immediate feedback from the I-CAT service. The control group will receive general information about cholesterol-related disease risk derived from existing materials prepared by the National Heart Foundation of Australia. Hyperlinks to a range of relevant websites will be provided.

In addition, after returning to the website at 8 weeks and providing follow-up information, all control group participants will receive the same tailored feedback from the I-CAT service as was given to the intervention group participants at randomisation. In this way, all study participants will ultimately receive the same advice but by providing one group with immediate advice and one group with delayed advice it will be possible to precisely and reliably determine the value of the I-CAT service to consumers.

All primary analyses will be of comparisons between the index cases in the intervention group and the index cases in the control group conducted according to the principle of intention-to-treat. For each outcome the analyses will compare the proportions of index cases reporting the outcome (or the mean values for each outcome) between randomised groups. Comparisons of proportions will be done using Chi-square tests and comparisons between means will be done using t-tests.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

The eligibility criteria for index cases will be:

  • Internet access
  • Informed consent
  • Resident in Australia
  • Prepared to answer some simple baseline questions about health
  • Prepared to return to the site on up to two occasions over the following 8-16 weeks to answer some brief follow-up questions, and
  • Not referred to the site by a friend of a relative already enrolled in the study (since they would then be a 'friend or relative' - see below).

A friend or relative of the index cases will be required to fulfil the same eligibility criteria except that they:

  • Will be provided with a modified information sheet and consent form congruent with their level of participation in the study
  • Will have been referred to the service by an index case, and
  • Will only be required to visit the site on one more occasion (after 8 weeks) to answer some brief follow-up questions.

Exclusion Criteria:

• Individual who is not residing in Australia

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00220974

Locations
Australia, New South Wales
The George Institute for International Health
Camperdown, New South Wales, Australia, 2050
Sponsors and Collaborators
The George Institute
Lipid and Cardiovascular Risk Assessment Service, ICPMR, Westmead Hospital
Royal Prince Alfred Hospital, Sydney, Australia
Pfizer
Medical benefit Fund (MBF)
Investigators
Principal Investigator: Bruce Neal, MB BS PhD The George Institute
  More Information

Additional Information:
No publications provided by The George Institute

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00220974     History of Changes
Other Study ID Numbers: I-CAT, I-CAT
Study First Received: September 13, 2005
Last Updated: February 11, 2009
Health Authority: Australia: Human Research Ethics Committee

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on July 20, 2014